Tim Watkins is a Director of Clinical Research in Respiratory/Inflammation Therapeutics at Gilead Sciences. He has over a decade of experience in the biomedical and biopharmaceutical sectors, with clinical research spanning ARDS, trauma, sepsis, viral pneumonia and other aspects of inflammatory and respiratory diseases. At Gilead, Tim is responsible for the clinical development of drug candidates targeting an array of inflammatory and respiratory conditions. Tim is highly involved in Gilead’s respiratory virus program specific to the development of presatovir, a small molecule for the treatment of RSV infection in healthy and immunocompromised adults. He has led a strategy team related to combination therapeutics for inflammatory indications. Tim is also a key member of Gilead’s filgotinib (JAKi) program, launching a new program in ocular inflammation specific to noninfectious uveitis.
Prior to joining Gilead, Tim served on the faculty of the Division of Pulmonary and Critical Care at the University of Washington (UW) and the PSBC Research Institute. He was a member of several research partnerships including the NIH/NHLBI-funded ARDSNet and the U.S. Critical Illness & Injury Trials Group. Tim completed his MD at Ohio State University followed by internal medicine training at the University of Wisconsin. He then completed sub-specialty training in Pulmonary & Critical Care Medicine at the UW in Seattle, where he also obtained a degree in Public Health – Epidemiology. Tim is a member of several professional societies including the American Thoracic Society where he serves as chair of the Drug/Device, Discovery and Development Committee.
